Orthofix Announces FDA Clearance and Initial Patient Implant with 3D-printed Titantium Interbody

Designed with nanoscale surface features, the CONSTRUX Mini Ti System is Orthofix’s first 3D-printed titanium (Ti) interbody introduced to the market.


LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and the first patient implant of the 3D-printed CONSTRUX™ Mini Ti Spacer System. Developed to enhance anterior cervical discectomy and fusion (ACDF) procedures, the CONSTRUX Mini Ti cervical spacer with Nanovate™ Technology is the first 3D-printed titanium interbody introduced to the market by Orthofix. “The ACDF procedure, which is often used to treat a herniated cervical disc or degenerative disc disease, involves replacing a patient’s damaged cervical disc with an interbody packed with a biologic to promote fusion in order to provide stability and strength to the area,” said Wayne Cheng, M.D., an orthopedic spine surgeon operating at Loma Linda University Medical Center in Loma Linda, CA, who performed the first patient implant procedure. “The CONSTRUX Mini Ti System’s optimized porosity and surface allows bone to grow into and through the spacer in order to aid with the patient’s fusion.” The CONSTRUX Mini Ti Spacer System with Nanovate Technology is one of many Orthofix products with nanotechnology FDA clearance including the CONSTRUX™ Mini PTC Spacer System, the Pillar™ SA PTC Spacer System, and the FORZA™ PTC Spacer System. When compared to solid PEEK devices, the 3D-printed endplates of these implants with Nanovate Technology show a significant increase in growth factors involved in osteogenesis and osteoblast maturation resulting in a more favorable osteogenic environment for bone ingrowth.

“Orthofix’s cervical spine offerings feature a wide array of implants ranging from motion-preserving products like the M6-C™ artificial cervical disc to advanced interbody and fixation solutions that aid surgeons in restoring spinal alignment and decreasing pain and nerve compression,” said Orthofix President of Global Spine Kevin Kenny. “We are dedicated to expanding our comprehensive cervical spine solutions with technologies like the CONSTRUX Mini Ti Spacer System that can make a meaningful difference in our product offerings and in the lives of patients.”

The CONSTRUX Mini Ti Spacer System features include:

  • 3D-printed porous titanium with macro, micro, and nanoscale surface features

  • Nanoscale surface that has been shown to increase proliferation and alkaline phosphatase activity (an early osteogenic differentiation marker) in human stem cells in vitro*

  • Endplates with 400 micron pores and 50-percent porosity designed to help facilitate bone ingrowth**

  • Functional gradient porous structure with 80-percent porosity at the midline of the implant which allows for increased fluoroscopic visualization

  • Large center opening with concaved inner walls for packing bone-grafting material

  • Straightforward instrumentation for easy implantation

Orthofix offers a comprehensive cervical portfolio with differentiated technologies across biologics, bone growth therapies and spinal implants. Learn more about our cervical solutions by visiting Orthofix.com.

*As suggested in an in vivo ovine lumbar spinal fusion model **In vitro performance may not be representative of clinical performance

About Orthofix Orthofix Medical Inc. is a global medical device and biologics company with a spine and extremities focus. The Company’s mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patients’ lives. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in more than 70 countries via the Company’s sales representatives and distributors. For more information, please visit www.Orthofix.com.

Forward-Looking Statements This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”). In addition to the risks described there, factors that could cause or contribute to such differences may include, but are not limited to: the risk that surgeons may be slow to adopt the CONSTRUX Mini Ti Spacer System; the risk that future patient studies or clinical experience and data may indicate that treatment with the CONSTRUX Mini Ti Spacer System does not improve patient outcomes as much as previously believed, or otherwise call into question the benefits of its use to patients, hospitals and surgeons; the risk that the product may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may decline to reimburse healthcare providers for the use of our products.

This list of risks, uncertainties and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

Contacts Alexa Huerta Investor Relations Tel 214 937 3190 alexahuerta@orthofix.com Denise Landry Media Relations Tel 214 937 2529


Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC